We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Design, Process Validation Lead to Warning for Acme

Design, Process Validation Lead to Warning for Acme

June 20, 2014

Acme Monaco received an FDA warning letter for failures related to design validation, process validation and other GMP issues.

According to the April 28 letter posted recently online, the company did not validate the design of its polytetrafluoroethylene-coated guidewires under actual or simulated conditions for use. Further, its risk analysis is inadequate because it doesn’t assess flaking and delaminating of the coating during use.

The New Britain, Conn., company, which makes guidewires for cardiovascular and urologic use, also lacks procedures to control changes to the device design, the letter says. Acme changed the formulation of the PTFE coating material “without any evaluation of validation, verification, review or approval prior to implementation of the change.”

According to the letter, Acme did not validate the following processes:

  • Cleaning of finished medical guidewires before coating using the Ultra Kool vapor immersion type solvent-based degreasing unit;
  • Post-coating of guidewires it contracts to outside vendors; and
  • Solvent-based cleaning of precoated guidewires using equipment designed and built by the company.

Corrective action slips also drew FDA scrutiny. The company did not implement identified corrective actions in response to a complaint about PTFE coating flaking during use. “You identified the need for an acceptance test to assess coating integrity for incoming coated guide wires received from outside vendors on 8/7/13, but did not implement action prior to shipping product from lot 056066-1-1A on 8/23/13 or lot 056066-1-1B on 10/3/13,” the letter says.

The company also failed to adequately investigate nonconforming product so it could identify all appropriate corrective actions.

For example, Acme identified nonconforming product in the inventory of one lot of guidewires that had been shipped. Out of 1,680 guidewires, 1,010 failed wet abrasion and tape tests for flaking coating and bent or bridging parts. But the investigation did not include a risk assessment to identify any health hazard associated with the distributed units, which did not undergo acceptance testing for coating integrity.

Acme did not respond to a request for comment by press time.

Prevent your company from receiving a warning letter due to process validation issues; purchase Devicemaker’s Guide to Process Validation now!

Medical Devices Inspections and Audits

Upcoming Events

  • 19Jan

    Pharmaceutical Quality Risk Management: Navigating the Intersection Between Regulatory Requirements & Risk Management

  • 21Jan

    Virtual MDSAP Audits in the Era of COVID-19: What to Know and Do to Pass Virtual Audits

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 27Jan

    FDA’s Response to COVID-19: Fundamentals of Obtaining Emergency Use Authorizations

  • 09Feb

    Maintaining Your Risk-Based Cleaning and Disinfectant Programs: Best Practices During COVID-19

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • Regeneron logo

    U.S. Government Orders More Supplies of Regeneron’s COVID-19 Antibody Cocktail

  • Siemens Healthineers logo

    Siemens Healthineers COVID Test Gets Additional Sampling Method Clearance

  • COVID-19  Clinical Trial

    Synairgen Initiates Dosing in Late-Stage Trial of Inhaled COVID-19 Therapy

  • Verona Pharma logo

    Verona Pharma Ends Enrollment in Inhaler-Administered COVID-19 Drug Pilot

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing